Pioglitazone and risk of bladder cancer

A meta-analysis of controlled studies

M. Ferwana, B. Firwana, R. Hasan, M. H. Al-Mallah, S. Kim, Victor Manuel Montori, Mohammad H Murad

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Aims: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analysis to evaluate the magnitude of this association and the quality of the supporting evidence. Methods: Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer. Results: Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow-up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09-1.39; I2 = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years. Conclusions: Patients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti-hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.

Original languageEnglish (US)
Pages (from-to)1026-1032
Number of pages7
JournalDiabetic Medicine
Volume30
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

pioglitazone
Urinary Bladder Neoplasms
Meta-Analysis
Type 2 Diabetes Mellitus
Patient Participation
Observational Studies

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Pioglitazone and risk of bladder cancer : A meta-analysis of controlled studies. / Ferwana, M.; Firwana, B.; Hasan, R.; Al-Mallah, M. H.; Kim, S.; Montori, Victor Manuel; Murad, Mohammad H.

In: Diabetic Medicine, Vol. 30, No. 9, 09.2013, p. 1026-1032.

Research output: Contribution to journalArticle

Ferwana, M. ; Firwana, B. ; Hasan, R. ; Al-Mallah, M. H. ; Kim, S. ; Montori, Victor Manuel ; Murad, Mohammad H. / Pioglitazone and risk of bladder cancer : A meta-analysis of controlled studies. In: Diabetic Medicine. 2013 ; Vol. 30, No. 9. pp. 1026-1032.
@article{4a81b18f444945e9bac93585f5285404,
title = "Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies",
abstract = "Aims: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analysis to evaluate the magnitude of this association and the quality of the supporting evidence. Methods: Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer. Results: Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow-up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95{\%} CI 1.09-1.39; I2 = 0{\%}) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years. Conclusions: Patients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti-hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.",
author = "M. Ferwana and B. Firwana and R. Hasan and Al-Mallah, {M. H.} and S. Kim and Montori, {Victor Manuel} and Murad, {Mohammad H}",
year = "2013",
month = "9",
doi = "10.1111/dme.12144",
language = "English (US)",
volume = "30",
pages = "1026--1032",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Pioglitazone and risk of bladder cancer

T2 - A meta-analysis of controlled studies

AU - Ferwana, M.

AU - Firwana, B.

AU - Hasan, R.

AU - Al-Mallah, M. H.

AU - Kim, S.

AU - Montori, Victor Manuel

AU - Murad, Mohammad H

PY - 2013/9

Y1 - 2013/9

N2 - Aims: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analysis to evaluate the magnitude of this association and the quality of the supporting evidence. Methods: Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer. Results: Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow-up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09-1.39; I2 = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years. Conclusions: Patients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti-hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.

AB - Aims: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analysis to evaluate the magnitude of this association and the quality of the supporting evidence. Methods: Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer. Results: Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow-up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09-1.39; I2 = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years. Conclusions: Patients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti-hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=84875166950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875166950&partnerID=8YFLogxK

U2 - 10.1111/dme.12144

DO - 10.1111/dme.12144

M3 - Article

VL - 30

SP - 1026

EP - 1032

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 9

ER -